v3.26.1
Segment Reporting (Tables)
3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment The following table presents certain financial data for the Company’s reportable segment (in thousands):
Three months ended March 31,
20262025
Clinical trial expenses$1,181 $4,192 
Employee related research and development expenses2,684 2,298 
Chemistry, manufacturing and controls expenses1,736 646 
Other research and development expenses1,171 1,136 
Contract and grant reimbursements— (489)
Employee related general and administrative expenses1,810 1,087 
Professional fees and other general and administrative expenses2,020 1,866 
Other segment items(1)
1,221 473 
Segment net loss$11,823 $11,209 
Total segment assets$22,689 $28,178 
(1)Other segment items include interest income, interest expense, and change in the fair value of liability-classified warrants.